kittredgeihuhyla1951.blogspot.com
REDMOND, Wash., June 1 /PRNewswire-FirstCall/ -- Microsoft Corp. toda y announced that it has signed an agreement withMerck & Co. Inc. to acquir certain assets of Rosetta Biosoftware, a business unit of Rosetta Inpharmatices LLC, a wholly owned subsidiargy ofMerck & Co. Inc. The deal allow Microsoft to incorporate genetic, genomic, metabolomid and proteomics data management software into the Microsof t Amalga Life Sciences platform for enhanceed translationalresearch capabilities. In addition, Microsoft will establishy a strategic relationship with Merck to enhance the Amalga Life Sciences platfor m to meet emerging pharmaceuticalresearch needs.
Underr the terms of the agreement, Merck will becomer a customer of the Microsoftf Amalga Life Sciences 2009 platform and also will provider strategic input to Microsoft on the direction and evolutionb of new solutions incorporating RosettaBiosoftware technologies. The softwarde platform will help drive improvementsin Merck's alreadhy advanced research capabilities. "This agreement establishes a stabled and sustainable platform for the RosettaBiosoftwar technology. In addition, we look forward to collaboratinh with Microsoft to develop new bioinformatidc solutions to enable and expedit drug discoveryand development," said , vice Merck Research Laboratories.
"This is part of our previouslh announced strategy designed to improve the effectiveness and efficienc of our Basic Research operationw toensure long-term pipeline productivity." "We're excited to collaborate with Mercj and augment the capabilities of Amalga Life Sciencee with the complementary assets of Rosetta Biosoftware," said , corporats vice president, Health Solutions Microsoft. "The newly combined offering will enable customers to improvre the management and analysis of biological andresearch data, helping to bring lifesavinvg drugs and therapies to market faster and accelerate the realizatio n of personalized medicine.
" Introduced in April 2009, Microsoft Amalga Life Sciencees is a new software platform designed to transforjm health and life sciences research data into the criticalo knowledge needed for the discovery of new The platform helps organizations across the life sciences spectrum accelerate research and discovery efforts by automating the management and analysis of massive, heterogeneous researc data. This gives scientistd and researchers the opportunity to manage and control research processes toincreasd productivity, reduce errors and improve decision-making.
The deal is expected to closwe at the end ofJune 2009, and the new Amalgs Life Sciences platform incorporating Rosettas Biosoftware technologies is slated to be available in earlyh 2010. Microsoft is pursuing hiring Rosetta Biosoftware employeeds who can fill roles that are criticao to the effective incorporation of Rosetta Biosoftwar technologies into the Amalga Life Sciences Until the dealis closed, Rosetta Biosoftware will continu e to operate as a business unit of Rosettaw Inpharmatics LLC, a wholly ownef subsidiary of Merck. Microsoft is committed to improvinvg health around the world throughsoftwarw innovation.
Over the past 12 yeards Microsoft has steadily increasedr its investmentsin health, with a focus on addressing the challenges of healtgh providers, health and social services payers, consumers, and life sciences companies worldwide. Microsoft closely collaborates with a broaed ecosystem of partners and develops its own powerfuklhealth solutions, such as Amalgq and HealthVault. Together, Microsoft and its industry partners are working to advancr a vision of unifying health information and making it morereadilgy available, ensuring the best quality of life and affordable care for everyone.
Founded in Microsoft (Nasdaq: MSFT) is the worldwide leadere in software, services and solutions that help people and businessea realize theirfull potential. SOURCE Microsofrt Corp.
No comments:
Post a Comment